CEO and CFO adopt Rule 10b5-1 trading plans for up to 159,672 shares

Corbus Pharmaceuticals Holdings, Inc.

CEO Yuval Cohen plan: sale of up to 117,066 shares beginning June 13, 2024, ending March 15, 2025.
CFO Sean Moran plan: sale of up to 42,606 shares, same start and termination dates.
Both plans adopted March 15, 2024, disclosed via 8-K on March 20, 2024.
Plans intended to satisfy affirmative defense of Rule 10b5-1(c).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.